Skip to content

Study · Non-randomized trial · n = 23 · 1990

4 results

[The immunocorrective therapy of pyoderma caused by staphylococci multiply resistant to antibiotics].

Rodionov AN, Khavinson VKh, Barbinov VV

Vestnik dermatologii i venerologii1 Jan 1990

PMID2327170 (opens in a new tab)PepBankPUB-02327170
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In chronic pyoderma patients, total bacterial antibiotic resistance in skin infection foci decreased after thymogen therapy.

    In plain wordsIn chronic pyoderma patients, bacterial antibiotic resistance at skin infection sites decreased after thymogen therapy.

    Peptide
    Thymogen (oglufanide)
    Outcome
    DecreaseTotal antibiotic resistance
    Study

    n = 23

    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A reduction of the total antibiotic resistance of the agent in foci of skin infection and normalization of the immunologic reactivity parameters were recorded in 23 patients with chronic pyodermas after a course of thymogen therapy.
  2. 02HumanNon-randomized trialEfficacy outcome

    In chronic pyoderma patients, immunologic reactivity parameters normalized after thymogen therapy.

    In plain wordsIn chronic pyoderma patients, immune reactivity measures normalized after thymogen therapy.

    Peptide
    Thymogen (oglufanide)
    Outcome
    Not applicableImmunologic reactivity parameters
    Study

    n = 23

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A reduction of the total antibiotic resistance of the agent in foci of skin infection and normalization of the immunologic reactivity parameters were recorded in 23 patients with chronic pyodermas after a course of thymogen therapy.
  3. 03HumanNon-randomized trialEfficacy outcome

    In pyoderma patients, thymogen increased total T lymphocyte counts.

    In plain wordsIn pyoderma patients, thymogen increased total T immune cell counts.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseTotal T lymphocyte count
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A new synthetic preparation of thymus, thymogen, had a modulating effect on the lymphocytes of pyoderma patients, manifesting by the increment of the total count of T-lymphocytes and T-helpers.
  4. 04HumanNon-randomized trialEfficacy outcome

    In pyoderma patients, thymogen increased T helper counts.

    In plain wordsIn pyoderma patients, thymogen increased helper T immune cell counts.

    Peptide
    Thymogen (oglufanide)
    Outcome
    IncreaseT helper count
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A new synthetic preparation of thymus, thymogen, had a modulating effect on the lymphocytes of pyoderma patients, manifesting by the increment of the total count of T-lymphocytes and T-helpers.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.